echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The overall growth of the pharmaceutical industry will slow down to about 10% of the main line of innovative pharmaceutical investment

    The overall growth of the pharmaceutical industry will slow down to about 10% of the main line of innovative pharmaceutical investment

    • Last Update: 2015-12-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: economic reference on December 1, 2015, the reporter of economic reference learned from the 28th China Pharmaceutical Industry Development Summit Forum held in Xiamen, Fujian Province on November 30 that relevant departments will speed up the review and approval of innovative drugs to prevent and control some major diseases, drugs listed in major national science and technology projects and national key R & D plans Participants generally believed that in 2015, the pharmaceutical industry ushered in a turning point, and the growth rate of the pharmaceutical industry slowed down to about 10% in the next few years, making it difficult to reproduce the overall opportunity But on the other hand, the demand is still rigid, and the long-term space is huge With the acceleration of new drug approval and the introduction of supporting policies, innovative drugs will become the main investment line of the pharmaceutical and biological industry To slow down the high growth of the pharmaceutical industry, Yu Mingde, President of China Pharmaceutical Enterprise Management Association, said at the meeting that in recent years, the revenue from drug production and sales has been growing steadily, with the total volume increasing, but the trend of slowing down is very clear "The first 30 years of reform and opening up have brought rapid growth to the pharmaceutical industry Last year, it was 2.45 trillion yuan, and this year, it is estimated that it is 2.7 trillion yuan, the absolute value is the highest level in history But in particular, the growth rate has been slowing down in recent years, and it's getting slower and slower " He said that since 2011, the growth rate has dropped from 20%, 18% and 13% to about 9%, which is expected to be about 9.1% or 9.2% this year A research report released by Guangfa Securities at the meeting also believed that at present, the coverage rate of medical insurance has exceeded 90% Under the background of medical insurance fee control and bidding price reduction, the growth rate of the industry has declined significantly In the past decade, the extensive development of the pharmaceutical industry has made it difficult to sustain the rapid growth model of interest related varieties such as traditional Chinese medicine injections and auxiliary drugs In 2014, the drug terminal market was about 1.25 trillion yuan, a year-on-year increase of 13%, and the industry is expected to grow by 10% in the next five years But on the other hand, the demand is still rigid and the prospect is still broad The proportion of elderly people over 60 increased from 7.5% in 1950 to 14.9% in 2015, including the major indications for malignancy, cerebrovascular disease, heart disease, hypertension and diabetes The incidence rate of elderly people over 65 accounted for 49% of all age groups According to the world bank, China's aging process will increase the burden of chronic diseases by 40% by 2030 In addition to the growth of demand, the unprecedented attention paid by the state to the pharmaceutical industry is also a good thing Wu Haidong, deputy director of the consumer goods department of the Ministry of industry and information technology of the people's Republic of China, said at the meeting that medicine is listed as a strategic emerging industry and a key development area of "made in China 2025", and its position is constantly improving "In the first three quarters of this year, the pharmaceutical industry maintained a good momentum, laying a good foundation for the start of the 13th five year plan." Wu Haidong said that since this year, the downward pressure on the national economy has been increasing In this context, the pharmaceutical industry has maintained a good momentum of operation From January to September, the added value of pharmaceutical industry increased by 10% year-on-year, 3.8 percentage points higher than that of all industries, and 3.1 percentage points higher than that of GDP He suggested that during the "13th five year plan" period, we should increase investment and improve efficiency A number of innovative drugs and high-performance medical devices have been approved for listing, and China has actively promoted the strategic transformation from tracking imitation to independent innovation The theme of this meeting is "big turning point, new blueprint for dream building" It is sponsored by China Pharmaceutical Enterprise Management Association, China over the counter drug association and China Pharmaceutical News Agency It is undertaken by unnamed biomedical Co., Ltd and implemented by Beijing saibailan Enterprise Management Co., Ltd Opportunities for innovative drugs and Biopharmaceutics will become the main investment line for the slowdown of industry growth Industry insiders believe that innovation is the only way for the pharmaceutical and biopharmaceutical industry to achieve "breakthrough" "If the U.S score is 95, then China's maximum score is 5 If it's ruthless, it's only 1." One scholar once described the gap between Chinese and foreign drug R & D capabilities Statistics show that the total number of drug approval numbers in China is up to 165000, including 102000 chemical drugs, over 95% of which are generic drugs, and less than 1% of which are truly innovative But the situation is gradually changing In recent years, listed companies have distributed innovative drugs and heavyweight biological drugs With the emergence of small molecule targeted drugs, immune monoclonal antibodies and new monoclonal antibodies, Chinese pharmaceutical enterprises are following the international innovation frontier and realizing leapfrog development In fact, innovative drugs and biological drugs are becoming the main investment line According to the statistics of investment group, in the second quarter of 2015, there were 29 financing cases in relevant fields in China, with a financing scale of 481 million US dollars, up nearly 62.83% compared with 295 million US dollars in the second quarter of 2014, showing a steady upward trend in both quantity and scale Pan Aihua, a Beijing University Weiming bioengineering Group Co., Ltd., told the economic reference newspaper that Weiming group will take advantage of China and its unique advantages to create an efficient R & D system for new drugs, and use the achievements of the world's new drug R & D with industrial value to build a "new drug R & D highway" around 2025 to solve the problem of Chinese taking drugs The specific target is: about 25 new drugs are approved every year, reducing the average R & D cost of each new drug to less than 50 million US dollars, and the average R & D time to about 8 years Speeding up the examination and approval of innovative drugs will obviously speed up It is worth mentioning that innovative drugs approved to go through the "green channel" of examination and approval will release sufficient market scale Innovative drugs refer to drugs with independent intellectual property patents Although new drug R & D has the characteristics of low success rate, high cost and long cycle, innovative drugs represent the core strength of pharmaceutical enterprises For a long time, the two bottleneck restricting local innovative drugs is slow progress in new drug approval and medical insurance payment However, it can be predicted that with the introduction of major national new drug projects and other policies, innovative drugs are expected to get priority approval opportunities, and the approval speed will be faster and faster The Chinese government's drug review policy was once regarded as an important gateway on the road of innovation According to the statistics of some institutions, it takes 18 months for innovative drugs from the submission of clinical application materials to the receipt of approval documents From the submission of materials to the receipt of feedback, Australia takes 5 days, the United States and South Korea take 1 month, Singapore takes 1 to 2 months, Brazil takes 2 months, the European Union takes 3 months, India and Russia take 3 to 4 months, Mexico takes 4 to 9 months In response, some regulatory officials said that according to the strategy of building an innovative country put forward by China, as the most innovative category of pharmaceutical industry and products, the state has given a high degree of attention and support, and given many preferential policies Pharmaceutical R & D has experienced an explosive growth, and the amount of application is very large In the past two or three years, drug review and approval have faced great difficulties The prominent problem is that the amount of R & D application is very high, but the speed of review and approval cannot keep up "As of August, there were about 21000 waiting for review The serious backlog has caused dissatisfaction among researchers and applicants, the public and the leaders of the State Council So we have to make major reforms in drug review and approval " The State Council's recently released opinions on reforming the review and approval system for pharmaceutical and medical devices clearly proposes to improve the quality of review and approval, solve the backlog of registration applications, improve the quality of generic drugs, encourage research and development of new drugs, and improve the transparency of review and approval, said the regulatory officials In this context, innovative drugs are the biggest beneficiaries of drug approval reform The next step, the officials said, is to speed up the review and approval of innovative drugs for the prevention and control of some major diseases, as well as drugs included in major national science and technology projects and key national R & D plans At the same time, the review and approval of innovative drugs and children's drugs transferred to domestic production, as well as innovative drugs using advanced preparation technology, innovative treatment means and obvious treatment advantages should also be accelerated Moreover, the approval of drug clinical trials will be greatly improved "In the past, the clinical examination and approval of innovative drugs were relatively conservative Enterprises were required to submit phase I and phase I reports When phase I was completed, enterprises were required to submit phase I reports When phase I was completed, enterprises were required to submit phase II reports When phase II was completed, enterprises were required to submit phase III reports However, the research and development speed of enterprises was delayed At the same time, the government also assumed too many responsibilities that enterprises should bear." The official explained that in the future, the approval of clinical work will be one-stop approval Phase I, II and III enterprises do it by themselves, with risks in the middle and prevention and control by themselves.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.